AlphaMadera's AlphaVal page computes Summit Therapeutics Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag SMMT as undervalued, fairly valued, or overvalued.

What is Summit Therapeutics Inc.'s fair value?

Fair value for SMMT is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value SMMT?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from SMMT's most recent reported fundamentals.

SMMT - Summit Therapeutics Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $19.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: SMMT has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.